Advertisement
Advertisement

JANX

JANX logo

Janux Therapeutics, Inc. Common Stock

13.70
USD
Sponsored
+0.18
+1.33%
Jun 16, 15:59 UTC -4
Closed
exchange

Pre-Market

13.69

-0.01
-0.07%

JANX Earnings Reports

Positive Surprise Ratio

JANX beat 14 of 20 last estimates.

70%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$12.60M
/
-$0.39
Implied change from Q1 26 (Revenue/ EPS)
+237.45%
/
--
Implied change from Q2 25 (Revenue/ EPS)
--
/
-29.09%

Janux Therapeutics, Inc. Common Stock earnings per share and revenue

On May 07, 2026, JANX reported earnings of -0.39 USD per share (EPS) for Q1 26, beating the estimate of -0.53 USD, resulting in a 27.36% surprise. Revenue reached 3.73 million, compared to an expected 3.91 million, with a -4.53% difference. The market reacted with a -2.51% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 15 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 12.60 million USD, implying an increase of 0.00% EPS, and increase of 237.45% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Greenwich LifeSciences, Inc.
Report Date
Jun 04, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.39
Surprise
-15.86%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Janux Therapeutics, Inc. Common Stock reported EPS of -$0.39, beating estimates by 27.36%, and revenue of $3.73M, -4.53% below expectations.
The stock price moved down -2.51%, changed from $14.54 before the earnings release to $14.18 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 15 analysts, Janux Therapeutics, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $12.60M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement